top of page

Cognitive and memory warning letters and litigation trends: Best practices for reducing risk

Asa Waldstein

Cognitive and memory warning letters and litigation trends: Best practices for reducing risk

Guest Article

Cognition and memory products are big business, and the Food and Drug Administration (FDA), National Advertising Division (NAD), Federal Trade Commission (FTC) and plaintiff attorneys are paying attention.

Cognition and memory products are big business, and the Food and Drug Administration (FDA), National Advertising Division (NAD), Federal Trade Commission (FTC) and plaintiff attorneys are paying attention.


This leads to warning letters, competitor challenges and lawsuits, but it can be confusing to know how to discuss ingredients and products without crossing the compliance line or becoming an easy lawsuit target. In this article, I’ll review enforcement trends and best practices to help keep you out of trouble while continuing to educate your consumers and grow your business.  

AHPA-member-logo.png
  • LinkedIn
  • YouTube
  • Facebook

American Herbal Products Association (AHPA) Member

©2024 by Supplement Advisory Group LLC. All Rights Reserved

Disclaimer: The educational information provided on this website is for informational purposes only. Contact an attorney for specific legal advice.  Rule #1 in compliance is to ensure marketing is truthful and not misleading.

Privacy Policy. |. Terms of Use. |. Sitemap

bottom of page